Ara
Toplam kayıt 36, listelenen: 21-30
TASL practice guidance on the clinical assessment and management of patients with nonalcoholic fatty liver disease
(Kare Publishing, 2023)
Nonalcoholic fatty liver disease (NAFLD) is a multisystem disease and is significantly associated with obesity, insulin resistance, type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease. NAFLD has become ...
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease
(SpringerNature, 2023)
Recompensation has gained increasing attention in the feld of cirrhosis,
particularly in chronic liver disease with a defnite aetiology. The current
global prevalence of obesity and nonalcoholic fatty liver disease
(NAFLD) ...
Chronotype preference, sleep quality, and night-eating behaviors in patients with metabolic dysfunction-associated steatotic liver disease: Assessing the relationship with disease severity and fibrosis
(Kare Publishing, 2023)
Background and Aim: Our primary objective is to examine the variance
in chronotype, night-eating patterns, and sleep quality in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease. In ...
A multi-society Delphi consensus statement on new fatty liver disease nomenclatureA multisociety Delphi consensus statement on new fatty liver disease nomenclature
(Elsevier, 2023)
The principal limitations of the terms nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. ...
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease
(Elsevier, 2023)
Background & Aims: Patients with fatty liver disease may experience stigma from the disease or comorbidities. In this crosssectional study, we aimed to understand stigma among patients with nonalcoholic fatty liver disease ...
Vibration-controlled transient elastography for non-invasive screening of liver fibrosis and steatosis in Turkish patients with A cross-sectional
(Kare Publishing, 2024)
Background and Aim: The prevalence of fibrosis and steatosis in patients with psoriasis, as determined by vibration-controlled transient elastography (VCTE), has not been evaluated in Turkiye to date. The present cross-sectional ...
Predicting fibrosis progression in non-alcoholic fatty liver disease patients using the FAST Score: A paired biopsy study
(Kare Publishing, 2024)
Background and Aim: This study aimed to investigate the predictive value of various non-invasive scores for identifying the progression of hepatic fibrosis over time in patients with Non-Alcoholic Fatty Liver Disease ...
Addressing the looming epidemic of metabolic dysfunction-associated steatotic liver disease in Pakistan: A call for action
(Kare Publishing, 2024)
The term metabolic dysfunction-associated steatotic liver disease
(MASLD), which evolved from its predecessor, nonalcoholic fatty liver
disease (NAFLD),[1]
Association of metabolic dysfunction-associated fatty liver disease with cognitive impairment and all-cause dementia: A comprehensive review
(AVES, 2024)
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a significant public health concern, affecting one-third of the global population and posing a risk for progressive liver disease. MAFLD is characterized by ...
The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement
(Wiley, 2024)
Background:Following the adoption of new nomenclature for steatotic liver disease, we aimed to build consensus on the use of International Classification of Diseases codes and recommendations for future research and ...